Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
09-Apr-2025 | 3,214.3 | 3,238.95 | 3,107.4 | 3,126.8 | 31,427 | 89,42,69,036.1 | 1,65,597 |
11-Apr-2025 | 3,145 | 3,192.05 | 3,123.65 | 3,129 | 37,991 | 1,32,68,19,779.4 | 2,66,616 |
15-Apr-2025 | 3,206.4 | 3,235 | 3,129 | 3,221.8 | 38,963 | 1,05,82,55,112.4 | 1,95,631 |
16-Apr-2025 | 3,225 | 3,260.2 | 3,200.5 | 3,222.7 | 27,166 | 67,90,27,873.2 | 1,12,620 |
17-Apr-2025 | 3,226.8 | 3,266.8 | 3,201.4 | 3,254.8 | 25,583 | 65,23,92,593.2 | 1,44,175 |
21-Apr-2025 | 3,280 | 3,284.3 | 3,231 | 3,254.6 | 19,441 | 55,07,86,963 | 1,05,439 |
22-Apr-2025 | 3,269.6 | 3,272.9 | 3,209.2 | 3,246.4 | 46,535 | 1,53,71,54,609.5 | 3,14,979 |
23-Apr-2025 | 3,260 | 3,354.9 | 3,230.1 | 3,332.4 | 32,180 | 1,29,09,76,511.4 | 2,31,852 |
24-Apr-2025 | 3,344.9 | 3,352.2 | 3,303 | 3,325.1 | 28,752 | 77,65,59,423.4 | 1,34,891 |
25-Apr-2025 | 3,349.1 | 3,349.1 | 3,168.8 | 3,238.9 | 39,728 | 1,06,95,99,785.8 | 1,71,475 |
28-Apr-2025 | 3,240 | 3,345.8 | 3,240 | 3,335 | 67,531 | 1,59,46,69,781 | 3,06,464 |
29-Apr-2025 | 3,348 | 3,351.4 | 3,307 | 3,322.7 | 27,203 | 60,22,16,461.7 | 91,019 |
30-Apr-2025 | 3,322.7 | 3,360 | 3,287.1 | 3,322 | 26,500 | 3,83,28,95,044.1 | 9,94,955 |
02-May-2025 | 3,312.5 | 3,325 | 3,226.6 | 3,255.2 | 21,538 | 45,89,03,077.5 | 80,900 |
05-May-2025 | 3,258.9 | 3,300 | 3,256.1 | 3,285.2 | 21,325 | 29,12,30,642.4 | 46,513 |
06-May-2025 | 3,287 | 3,299.8 | 3,237.9 | 3,270.1 | 20,949 | 39,80,85,094.8 | 60,405 |
07-May-2025 | 3,164.7 | 3,300 | 3,164.7 | 3,291.1 | 33,374 | 84,43,53,951.8 | 1,67,116 |
08-May-2025 | 3,315 | 3,327 | 3,170.7 | 3,185.8 | 37,126 | 69,23,74,873.1 | 88,038 |
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Bajaj Finance, Vedanta, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
